PT97237A - Processo para a preparacao de novos peptideos inibidores da agregacao de plaquetas - Google Patents

Processo para a preparacao de novos peptideos inibidores da agregacao de plaquetas Download PDF

Info

Publication number: PT97237A
Authority: PT; Portugal
Prior art keywords: formula; compounds; prepared; process according; compound
Prior art date: 1990-04-05

Application number

PT97237A

Other languages

English (en)

Portuguese (pt)

Inventor

Mark Christopher Allen

Peter Daniel Kane

Roy Wade

Original Assignee

Ciba Geigy Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-04-05

Filing date

1991-04-03

Publication date

1992-01-31

1991-04-03 Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag

1992-01-31 Publication of PT97237A publication Critical patent/PT97237A/pt

Links

238000000034 method Methods 0.000 title claims description 22
230000008569 process Effects 0.000 title claims description 15
238000002360 preparation method Methods 0.000 title claims description 5
230000002776 aggregation Effects 0.000 title description 7
238000004220 aggregation Methods 0.000 title description 7
239000003112 inhibitor Substances 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims description 39
235000001014 amino acid Nutrition 0.000 claims description 15
150000001413 amino acids Chemical class 0.000 claims description 15
-1 4- (hydroxymethyl) -thiophene-4-carboxylic acid Chemical compound 0.000 claims description 13
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 9
229920005989 resin Polymers 0.000 claims description 9
239000011347 resin Substances 0.000 claims description 9
235000008206 alpha-amino acids Nutrition 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 5
125000002252 acyl group Chemical group 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
238000011282 treatment Methods 0.000 claims description 5
150000001408 amides Chemical class 0.000 claims description 4
125000000732 arylene group Chemical group 0.000 claims description 4
230000008878 coupling Effects 0.000 claims description 4
238000010168 coupling process Methods 0.000 claims description 4
238000005859 coupling reaction Methods 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
125000004450 alkenylene group Chemical group 0.000 claims description 3
150000001371 alpha-amino acids Chemical class 0.000 claims description 3
229910052739 hydrogen Inorganic materials 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
239000002253 acid Substances 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims 1
125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims 1
125000001072 heteroaryl group Chemical group 0.000 claims 1
210000000582 semen Anatomy 0.000 claims 1
210000002268 wool Anatomy 0.000 claims 1
210000001772 blood platelet Anatomy 0.000 description 13
239000013543 active substance Substances 0.000 description 11
229940024606 amino acid Drugs 0.000 description 11
108090000765 processed proteins & peptides Proteins 0.000 description 10
102000008946 Fibrinogen Human genes 0.000 description 8
108010049003 Fibrinogen Proteins 0.000 description 8
229940012952 fibrinogen Drugs 0.000 description 8
239000000825 pharmaceutical preparation Substances 0.000 description 8
230000000694 effects Effects 0.000 description 5
208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
150000003862 amino acid derivatives Chemical class 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000000576 coating method Methods 0.000 description 4
239000008298 dragée Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
150000001370 alpha-amino acid derivatives Chemical class 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229960005190 phenylalanine Drugs 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
230000004044 response Effects 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000000243 solution Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
125000001424 substituent group Chemical group 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
150000003626 triacylglycerols Chemical class 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108090000317 Chymotrypsin Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
229960005261 aspartic acid Drugs 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
238000003556 assay Methods 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000023555 blood coagulation Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
125000001589 carboacyl group Chemical group 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
210000002381 plasma Anatomy 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
238000012216 screening Methods 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
229960004295 valine Drugs 0.000 description 2
125000002030 1,2-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([*:2])C([H])=C1[H] 0.000 description 1
125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
XLBBKEHLEPNMMF-SSUNCQRMSA-N 129038-42-2 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)[C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=CC=C1 XLBBKEHLEPNMMF-SSUNCQRMSA-N 0.000 description 1
RDFMDVXONNIGBC-UHFFFAOYSA-N 2-aminoheptanoic acid Chemical compound CCCCCC(N)C(O)=O RDFMDVXONNIGBC-UHFFFAOYSA-N 0.000 description 1
XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 description 1
101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
239000004201 L-cysteine Substances 0.000 description 1
235000013878 L-cysteine Nutrition 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
229930182844 L-isoleucine Natural products 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
235000019454 L-leucine Nutrition 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
229930195722 L-methionine Natural products 0.000 description 1
229930182821 L-proline Natural products 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
239000011149 active material Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229960003767 alanine Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
125000003435 aroyl group Chemical group 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000035602 clotting Effects 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
108010025752 echistatin Proteins 0.000 description 1
108010062797 equistatin Proteins 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000005549 heteroarylene group Chemical group 0.000 description 1
238000011141 high resolution liquid chromatography Methods 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
230000000899 immune system response Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000004957 immunoregulator effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960004452 methionine Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000000896 monocarboxylic acid group Chemical group 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004957 naphthylene group Chemical group 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000000049 pigment Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920005990 polystyrene resin Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
229960002429 proline Drugs 0.000 description 1
125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000005550 pyrazinylene group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000005576 pyrimidinylene group Chemical group 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
230000007017 scission Effects 0.000 description 1
229960001153 serine Drugs 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035939 shock Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
101150035983 str1 gene Proteins 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000003826 tablet Substances 0.000 description 1
229960002898 threonine Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960004799 tryptophan Drugs 0.000 description 1
229960004441 tyrosine Drugs 0.000 description 1
239000004474 valine Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Crystallography & Structural Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

PT97237A 1990-04-05 1991-04-03 Processo para a preparacao de novos peptideos inibidores da agregacao de plaquetas PT97237A (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB909007751A GB9007751D0 (en)	1990-04-05	1990-04-05	Novel platelet-aggregation inhibitors

Publications (1)

Publication Number	Publication Date
PT97237A true PT97237A (pt)	1992-01-31

Family

ID=10673967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT97237A PT97237A (pt)	1990-04-05	1991-04-03	Processo para a preparacao de novos peptideos inibidores da agregacao de plaquetas

Country Status (13)

Country	Link
EP (1)	EP0452257A3 (de)
JP (1)	JPH0770174A (de)
KR (1)	KR910018404A (de)
AU (1)	AU7410191A (de)
CA (1)	CA2039628A1 (de)
FI (1)	FI911606A7 (de)
GB (1)	GB9007751D0 (de)
IE (1)	IE911127A1 (de)
NO (1)	NO911327L (de)
NZ (1)	NZ237674A (de)
PT (1)	PT97237A (de)
TW (1)	TW206238B (de)
ZA (1)	ZA912498B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5332726A (en) *	1989-09-29	1994-07-26	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Antithrombotic peptides and pseudopeptides
JPH08503920A (ja) *	1991-04-11	1996-04-30	ローヌ−プーランローラーインターナショナル（ホウルディングス）インコーポレイテッド	抗血栓ペプチドおよび偽ペプチド誘導体
DE4126277A1 (de) *	1991-08-08	1993-02-11	Cassella Ag	Hydantoinderivate
CA2101599A1 (en) *	1992-08-31	1994-03-01	Wilhelm Bannwarth	Tri- and tetracyclic compounds
US5652242A (en) *	1993-03-29	1997-07-29	Zeneca Limited	Heterocyclic derivatives
US5753659A (en) *	1993-03-29	1998-05-19	Zeneca Limited	Heterocyclic compouds
EP0690847A1 (de) *	1993-03-29	1996-01-10	Zeneca Limited	Heterozyklische derivate als plätchenaggregationsinhibitoren
US5750754A (en) *	1993-03-29	1998-05-12	Zeneca Limited	Heterocyclic compounds
AU692438B2 (en) *	1993-03-29	1998-06-11	Astrazeneca Ab	Heterocyclic derivatives as platelet aggregation inhibitors
GB9313268D0 (en) *	1993-06-28	1993-08-11	Zeneca Ltd	Chemical compounds
US5463011A (en) *	1993-06-28	1995-10-31	Zeneca Limited	Acid derivatives
GB9313285D0 (en) *	1993-06-28	1993-08-11	Zeneca Ltd	Acid derivatives
US5780590A (en) *	1993-10-15	1998-07-14	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptides
DE19621638C2 (de) *	1996-05-30	2002-06-27	Fraunhofer Ges Forschung	Offenzellige Schaumkeramik mit hoher Festigkeit und Verfahren zu deren Herstellung
DE19632773A1 (de) *	1996-08-14	1998-02-19	Basf Ag	Neue Thrombininhibitoren
GB9826751D0 (en)	1998-12-05	1999-01-27	British Aerospace	Method for increasing the signal to noise ratio in non-destructive testing

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3781263T2 (de) *	1986-12-15	1993-04-08	Inst Nat Sante Rech Med	Peptid-derivate und deren verwendung in der therapie.
CA2008116C (en) *	1989-02-23	2001-11-20	Thomas Weller	Glycine derivatives

1990
- 1990-04-05 GB GB909007751A patent/GB9007751D0/en active Pending
1991
- 1991-03-26 EP EP19910810219 patent/EP0452257A3/en not_active Withdrawn
- 1991-04-03 CA CA002039628A patent/CA2039628A1/en not_active Abandoned
- 1991-04-03 FI FI911606A patent/FI911606A7/fi not_active Application Discontinuation
- 1991-04-03 NZ NZ237674A patent/NZ237674A/en unknown
- 1991-04-03 PT PT97237A patent/PT97237A/pt not_active Application Discontinuation
- 1991-04-03 KR KR1019910005349A patent/KR910018404A/ko not_active Withdrawn
- 1991-04-04 IE IE112791A patent/IE911127A1/en unknown
- 1991-04-04 JP JP3071540A patent/JPH0770174A/ja active Pending
- 1991-04-04 NO NO91911327A patent/NO911327L/no unknown
- 1991-04-04 ZA ZA912498A patent/ZA912498B/xx unknown
- 1991-04-04 AU AU74101/91A patent/AU7410191A/en not_active Abandoned
- 1991-04-13 TW TW080102866A patent/TW206238B/zh active

Also Published As

Publication number	Publication date
NZ237674A (en)	1992-07-28
FI911606A7 (fi)	1991-10-06
ZA912498B (en)	1992-01-29
EP0452257A2 (de)	1991-10-16
EP0452257A3 (en)	1992-09-02
GB9007751D0 (en)	1990-06-06
IE911127A1 (en)	1991-10-09
CA2039628A1 (en)	1991-10-06
FI911606A0 (fi)	1991-04-03
NO911327D0 (no)	1991-04-04
KR910018404A (ko)	1991-11-30
AU7410191A (en)	1991-10-10
JPH0770174A (ja)	1995-03-14
NO911327L (no)	1991-10-07
TW206238B (de)	1993-05-21

Legal Events

Date	Code	Title	Description
1992-01-31	BB1A	Laying open of patent application	Effective date: 19910911
1998-02-27	FC3A	Refusal	Effective date: 19971120

Publication	Publication Date	Title
PT97237A (pt)	1992-01-31	Processo para a preparacao de novos peptideos inibidores da agregacao de plaquetas
AU732299B2 (en)	2001-04-12	Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof
CA2338524C (en)	2013-01-22	Inhibitors of urokinase and blood vessel formation
CA1326326C (en)	1994-01-18	Platelet-aggregation inhibitors
Gacel et al.	1981	Evidence of the preferential involvement of. mu.-receptors in analgesia using enkephalins highly selective for peripheral. mu. or. delta. receptors
PT91828A (pt)	1990-03-30	Processo para a preparacao de peptideos inibidores de proteases do hiv, uteis para o tratamento da sida
JP7429726B2 (ja)	2024-02-08	α４β７インテグリンを標的とする環状ペプチド多量体
US5700779A (en)	1997-12-23	Bradykinin antagonist peptides incorporating N-substituted glycines
EP0498268A2 (de)	1992-08-12	5-Oxo-L-Prolinderivate und deren pharmazeutischen Herstellungen
AU2010321240A1 (en)	2012-06-07	Template-fixed peptidomimetics with CCR10 antagonistic activty
RU2116312C1 (ru)	1998-07-27	Производные пептида или их соли, фармацевтическая композиция
CN113999237A (zh)	2022-02-01	一种核苷类前药及其用途
KR0121793B1 (ko)	1997-11-27	L-프롤린 유도체, 이의 제조 방법 및 이를 함유하는 향정신성 생물학적 제제
AU2001280052B2 (en)	2007-11-29	Pharmaceutical composition comprising an analgesic peptide
Heimbrook et al.	1991	Gastrin releasing peptide antagonists with improved potency and stability
JPH09507213A (ja)	1997-07-22	抗血栓性アザシクロアルキルアルカノイルペプチド及びプソイドペプチド
ES2390052T3 (es)	2012-11-06	Agonistas del receptor opioide kappa que comprende un derivado de 2-fenilbenzotiazolina
Stoffel et al.	1961	Synthesis of structures related to bacitracin A
CA3188364A1 (en)	2022-02-10	Methods for the synthesis of protein-drug conjugates
KR950001634B1 (ko)	1995-02-27	아미노산 유도체
RU2168493C2 (ru)	2001-06-10	Производные l-аргинина, способ их получения, фармацевтическая композиция, обладающая ингибирующей no-синтазу активностью
WO2003097670A1 (es)	2003-11-27	Compuestos capaces de bloquear la respuesta a sustancias químicas o estímulos térmicos o mediadores de la inflamación de los nociceptores, un método para su obtención y composiciones que los contienen
ES3005857T3 (en)	2025-03-17	Novel peptoids and use thereof for preventing or treating chronic pain
IE42249B1 (en)	1980-07-02	Octapeptide derivatives having an oxygen or sulfur containing moiety in the c-terminal position
SK282760B6 (sk)	2002-12-03	Antagonista LH-RH, spôsob jeho prípravy, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje